Tendencias y variabilidad en el uso de glucocorticoides en los pacientes con lupus eritematoso sistémico incluidos en el registro RELESSER-PROS

IF 1.5 Q4 RHEUMATOLOGY

Reumatologia Clinica Pub Date : 2026-10-01 Epub Date: 2026-09-15 DOI:10.1016/j.reuma.2026.502220

Inigo Rua-Figueroa, David Fernández-Fernández, Zulema Plaza, Karen Roberts, Belén Serrano-Benavente, María Galindo-Izquierdo, Jaime Calvo Alen, Raúl Menor, Natalia Mena-Vázquez, Esther Uriarte, Eva Tomero, Mercedes Freire, Clara Sanguesa, Silvia Gómez-Sabater, Loreto Horcada, Nuria Lozano-Rivas, María Jesús García-Villanueva, Adrián Quevedo-Rodríguez, Elvira Díez-Álvarez, Javier Narváez, Jose M. Pego-Reigosa

{"title":"Tendencias y variabilidad en el uso de glucocorticoides en los pacientes con lupus eritematoso sistémico incluidos en el registro RELESSER-PROS","authors":"Inigo Rua-Figueroa, David Fernández-Fernández, Zulema Plaza, Karen Roberts, Belén Serrano-Benavente, María Galindo-Izquierdo, Jaime Calvo Alen, Raúl Menor, Natalia Mena-Vázquez, Esther Uriarte, Eva Tomero, Mercedes Freire, Clara Sanguesa, Silvia Gómez-Sabater, Loreto Horcada, Nuria Lozano-Rivas, María Jesús García-Villanueva, Adrián Quevedo-Rodríguez, Elvira Díez-Álvarez, Javier Narváez, Jose M. Pego-Reigosa","doi":"10.1016/j.reuma.2026.502220","DOIUrl":null,"url":null,"abstract":"<div><h3>Context</h3><div>Recommendations for the management of systemic lupus erythematosus (SLE) advocate increasingly restrictive use of glucocorticoids (GC). However, there are no wide-scale data on their use in clinical practice from Spain, nor on compliance with current recommendations. The objective was to analyze this aspect of SLE treatment by autonomous communities (CCAA).</div></div><div><h3>Methods</h3><div>Observational, descriptive, longitudinal, and prospective study of patients with SLE included in RELESSER-PROS regarding patterns of GC use.</div></div><div><h3>Results</h3><div>1,432 patients were included, 89.8% women, mean age 56 years (±13.6), median follow-up 3.80 [2.06, 4.18] years, from 2015 to 2021. Median S-SLEDAI (5 visits): 2.00 [Q-Q3] [0-4.00], PGA: 0.3 [0,0.9]. Median SLICC/ARC DI: 0 [0-1.00], mean: 0.83 (±1.20). Between 30% and 61% of patients received GC at baseline and between 17% and 50% at the end (V5). A progressive decrease in the percentage of patients receiving GC was observed in most CCAs, reaching the minimum at V5. Between 71.45% and 89.47% of patients, by autonomous community, met the criterion of ≤5mg of prednisone at V5, with a delta between the autonomous community with the highest percentage and the lowest of 18 points. This percentage increased between visit 1 and visit 5 in all cases.</div></div><div><h3>Conclusions</h3><div>The use of low-dose GCs is common in Spanish lupus patients, although there is a clear downward trend in their use. Most patients typically reach the recommended dose. There are differences between the different autonomous communities in the use of GCs and their dosage.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 8","pages":"Article 502220"},"PeriodicalIF":1.5000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X26001622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Context

Recommendations for the management of systemic lupus erythematosus (SLE) advocate increasingly restrictive use of glucocorticoids (GC). However, there are no wide-scale data on their use in clinical practice from Spain, nor on compliance with current recommendations. The objective was to analyze this aspect of SLE treatment by autonomous communities (CCAA).

Methods

Observational, descriptive, longitudinal, and prospective study of patients with SLE included in RELESSER-PROS regarding patterns of GC use.

Results

1,432 patients were included, 89.8% women, mean age 56 years (±13.6), median follow-up 3.80 [2.06, 4.18] years, from 2015 to 2021. Median S-SLEDAI (5 visits): 2.00 [Q-Q3] [0-4.00], PGA: 0.3 [0,0.9]. Median SLICC/ARC DI: 0 [0-1.00], mean: 0.83 (±1.20). Between 30% and 61% of patients received GC at baseline and between 17% and 50% at the end (V5). A progressive decrease in the percentage of patients receiving GC was observed in most CCAs, reaching the minimum at V5. Between 71.45% and 89.47% of patients, by autonomous community, met the criterion of ≤5 mg of prednisone at V5, with a delta between the autonomous community with the highest percentage and the lowest of 18 points. This percentage increased between visit 1 and visit 5 in all cases.

Conclusions

The use of low-dose GCs is common in Spanish lupus patients, although there is a clear downward trend in their use. Most patients typically reach the recommended dose. There are differences between the different autonomous communities in the use of GCs and their dosage.

查看原文本刊更多论文

RELESSER-PROS登记的系统性红斑狼疮患者中糖皮质激素使用的趋势和变异性

背景：对于系统性红斑狼疮（SLE）的治疗建议提倡越来越严格地使用糖皮质激素（GC）。然而，在西班牙的临床实践中，没有关于它们的使用的大规模数据，也没有关于当前建议的依从性的数据。目的是分析自治区（CCAA） SLE治疗的这一方面。方法对纳入releser - pros的SLE患者进行关于GC使用模式的观察性、描述性、纵向和前瞻性研究。结果纳入1432例患者，女性89.8%，平均年龄56岁（±13.6）岁，中位随访3.80[2.06,4.18]年，时间为2015 - 2021年。S-SLEDAI中位数（5次就诊）：2.00 [Q-Q3] [0-4.00], PGA: 0.3[0,0.9]。中位SLICC/ARC DI: 0[0-1.00]，平均值：0.83（±1.20）。30% - 61%的患者在基线时接受了GC治疗，17% - 50%的患者在终点接受了GC治疗（V5）。在大多数cca中，观察到接受GC的患者百分比逐渐下降，在V5时达到最低。71.45% ~ 89.47%的自治区患者符合强的松V5≤5mg的标准，最高的自治区与最低的自治区之间的差值为18点。在所有病例中，这一比例在第1次访问和第5次访问之间都有所增加。结论在西班牙狼疮患者中，低剂量GCs的使用是常见的，尽管其使用有明显的下降趋势。大多数患者通常达到推荐剂量。不同的自治区在GCs的使用和剂量方面存在差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatologia Clinica RHEUMATOLOGY-

CiteScore

2.40

自引率

6.70%

发文量

105

审稿时长

54 days

期刊介绍： Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.